Medicinal composition for auxiliary treatment of diabetic coronary artery disease

An adjuvant therapy, diabetic technology, applied in the field of new pharmaceutical composition

Inactive Publication Date: 2012-11-28
王丽香
View PDF3 Cites 2 Cited by
  • Summary
  • Abstract
  • Description
  • Claims
  • Application Information

AI Technical Summary

Problems solved by technology

[0004] At present, there is a lack of daily health care medicines for preventing coronary heart disease and delaying the onset of coronary heart disease in diabetic patients before and after coronary heart disease is diagnosed

Method used

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more

Image

Smart Image Click on the blue labels to locate them in the text.
Viewing Examples
Smart Image
  • Medicinal composition for auxiliary treatment of diabetic coronary artery disease

Examples

Experimental program
Comparison scheme
Effect test

preparation example Construction

[0025] Preparation of Astragalus and Gymnema Leaf Extract:

[0026] 1) Extract astragalus and Gymnema leaves with 8-20 times the volume of 40-95% ethanol at a temperature of 50-80°C, and extract the medicinal materials for 1-3 times, each time for 1-3 hours;

[0027] 2) Combine the extracts, concentrate, and prepare a specific gravity of 1.3-1.8g / cm 3 thick paste;

[0028] 3) drying the thick paste prepared in 2) until the water content is less than 3% by weight, and pulverizing to obtain extracts of leaves of Astragalus membranaceus and Gymnema sp.;

[0029] Green tea extract is commercially available, which contains 15%-98% of epigallocatechin gallate (EGCG);

[0030] Vitamin D is a commercially available raw material.

[0031] Among them, the leaves of Astragalus membranaceus and Gymnema sylvestris are extracted by heating with alcohol. This process has been verified to be able to effectively extract astragaloside IV and Gymnemic acid. Among them, the extraction rate...

Embodiment 1

[0042] Example 1 A pharmaceutical composition for adjuvant treatment of diabetic coronary heart disease

[0043] The composition consists of the following components, and the daily dosage of each component is:

[0044] Astragalus 10g

[0045] Gymnema leaves 10g

[0046] Green Tea Extract 3g

[0047] Vitamin D 600IU

Embodiment 2

[0048] Embodiment 2 For the pharmaceutical composition of embodiment 1, the extraction of its active ingredient

[0049] 1) Extract 10g of Radix Astragali and 10g spoonfuls of Gymnema leaves with 200ml of 85% by volume ethanol at a temperature of 75°C, and extract the medicinal materials 3 times, 1 hour each time;

[0050] 2) Combine the extracts, filter, under 0.1Mpa, the temperature is 60°C, concentrate under reduced pressure to recover ethanol, the specific gravity of the preparation is 1.55g / cm 3 thick cream 6.18g;

[0051] 3) Dry the thick paste prepared in 2) at 800 Pa at a temperature of 80°C until the water content is less than 3% by weight, and pulverize to obtain 4.1 g of Radix Astragali and Gymnema Gymnema Leaf Extract; wherein the content of Astragaloside IV is 0.2% , the content of gymnemic acid is 0.7%.

[0052] The green tea extract is a commercially available product, which contains 43.5% by weight of epigallocatechin gallate (EGCG), and weighs 3g;

[0053]...

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to view more

PUM

No PUM Login to view more

Abstract

The invention relates to a medicinal composition for auxiliary treatment of diabetic coronary artery disease, which comprises the following components by weight (namely daily dosage): 1 to 50g of astragalus mongholicus, 1 to 50g of folium gymnemae, 1 to 20g of green tea extract, and 400 to 2,000IU of vitamin D, wherein the astragalus mongholicus and the folium gymnemae are subjected to alcohol heat extraction to obtain astragalus mongholicus and folium gymnemae extracts, and the contents of astragaloside and gymnemic acid can be detected; and the green tea extract and the vitamin D are mixed, and an excipient is added to prepare various oral preparations. The astragaloside can be used for reducing blood sugar; the green tea extract can be used for increasing HDL-C (high-density lipoproteincholesterol), reducing LDL-C (low-density lipoprotein cholesterol), and improving the blood situation of a patient; the astragaloside has the function of protecting heart and blood vessels; and the vitamin D has the effect of strengthening the curative effect of the Chinese medicament. Clinical applications prove that the medicinal composition can be used for assisting treatment of the patient with diabetic coronary artery disease, and remarkable effects can be obtained.

Description

technical field [0001] The invention relates to a new pharmaceutical composition, which plays the role of auxiliary drug treatment, in particular to a pharmaceutical composition for auxiliary treatment of diabetic coronary heart disease. Background technique [0002] Diabetes and coronary heart disease have become two major diseases that threaten human health. Coronary heart disease occurs in 55% of adults with diabetes. ESC is one of the drafters of the guidelines for the diagnosis and treatment of diabetes and cardiovascular disease (CVD). Professor Lars Ryden of the Swedish Karolinska Institute pointed out that there is an inseparable relationship between abnormal glucose metabolism and CVD. Abnormal glucose metabolism increases the incidence and mortality of CVD. The incidence and mortality of coronary heart disease in diabetic patients are 2 to 4 times that of those without diabetes. Coronary heart disease, as the main complication of diabetes, is the most common cau...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to view more

Application Information

Patent Timeline
no application Login to view more
Patent Type & Authority Applications(China)
IPC IPC(8): A61K36/82A61P3/10A61P9/10
Inventor 苏建丽
Owner 王丽香
Who we serve
  • R&D Engineer
  • R&D Manager
  • IP Professional
Why Eureka
  • Industry Leading Data Capabilities
  • Powerful AI technology
  • Patent DNA Extraction
Social media
Try Eureka
PatSnap group products

Browse by: Latest US Patents, China's latest patents, Technical Efficacy Thesaurus, Application Domain, Technology Topic.

© 2024 PatSnap. All rights reserved.Legal|Privacy policy|Modern Slavery Act Transparency Statement|Sitemap